Myelodysplastic Syndrome – VJRegenMed

Allogeneic NKX101 in liver cancer

Simon Ng — Tue, 26 Oct 2021 09:52:59 +0000

Kanya Rajangam, MD, PhD, NKarta Therapeutics, South San Francisco, CA, discusses NKX101 in solid tumor indications. NKX101, an allogeneic NKG2D receptor chimeric antigen receptor (CAR) natural killer (NK) cell therapy, is currently being assessed in patients with relapsed/refractory acute myeloid leukemia (AML) or high risk myelodysplastic syndromes (MDS) in a Phase I trial (NCT04623944). In addition to AML and MDS, NKX101 use is being extended to liver localized tumors including hepatocellular carcinoma (HCC) and metastatic colorectal cancer. Transarterial delivery will enable successful trafficking of the cell therapy to the tumor by concentrating NKX101 in the tumor. This interview took place at Meeting on the Mesa 2021.

CYCLE-1: next generation NKG2D-based CAR T-cells in AML/MDS

admin_vjr_user — Wed, 10 Mar 2021 19:30:16 +0000

David Gilham, PhD, Celyad Oncology, Mont-Saint-Guibert, Belgium, describes the ongoing Phase 1 CYCLE-1 dose-escalation study (NCT04167696) of CYAD-02, an investigational autologous CAR-T cell therapy that is engineered to express both the natural killer group 2D (NKG2D) receptor and short hairpin RNA (shRNA), in patients with relapsed/refractory acute myeloid leukemia (r/r AML) or myelodysplastic syndrome (MDS). This study aims to determine the recommended dose of CYAD-02 and evaluate safety and clinical activity of a single infusion of CYAD-02 following preconditioning chemotherapy in patients with r/r AML or MDS. This interview took place during the CAR-TCR Summit Europe 2021.